Marketdash

Big Pre-Market Losers: Travere Therapeutics Tumbles 28% on Corporate Update

MarketDash Editorial Team
2 hours ago
Travere Therapeutics led the pack of declining stocks in Tuesday's pre-market session, plunging 28% after issuing its 2026 outlook and announcing plans to restart a Phase 3 study. Sony and several Chinese tech names also slid as futures pointed lower.

Get Market Alerts

Weekly insights + SMS alerts

Tuesday's pre-market session brought a wave of selling pressure, with U.S. stock futures edging lower and Dow futures down around 0.2%.

The morning's biggest casualty was Travere Therapeutics Inc. (TVTX), which took a beating after dropping a corporate update and its 2026 outlook. The biotech company expects total U.S. net product sales of $127 million for the fourth quarter, with full-year 2025 U.S. net product sales projected at $410 million. Perhaps more significantly, Travere announced it will restart its Phase 3 HARMONY study in the first quarter of 2026.

The market wasn't thrilled with the news. Travere Therapeutics shares cratered 28.2% to $24.50 in pre-market trading.

But Travere wasn't alone in the pre-market pain. Here's who else was taking hits before the opening bell:

Lulu's Fashion Lounge Holdings Inc. (LVLU) gave back some of Monday's euphoria, sliding 10.4% to $10.89. The fashion retailer had surged 79% the previous session after Friedland Enterprises scooped up a 5% stake in the company.

Graf Global Corp (GRAF) tumbled 7% to $10.00 in pre-market action.

Ready Capital Corp (RC) declined 4.3% to $2.01 before the bell.

Chinese tech stocks pulled back after Monday's rally. Baidu Inc. (BIDU) dropped 3.9% to $146.40 after gaining 6% on Monday, while PDD Holdings Inc. (PDD) fell 3.8% to $114.22.

Amrize AG (AMRZ) dipped 3.7% to $55.51, and DeFi Technologies Inc. (DEFT) declined 3.7% to $1.04 in early trading.

Kingsoft Cloud Holdings Ltd (KC) fell 3.5% to $12.93, reversing some of Monday's impressive 22% jump.

Sony Group Corp (SONY) rounded out the decliners, falling 3.3% to $24.34 in pre-market trading.

Big Pre-Market Losers: Travere Therapeutics Tumbles 28% on Corporate Update

MarketDash Editorial Team
2 hours ago
Travere Therapeutics led the pack of declining stocks in Tuesday's pre-market session, plunging 28% after issuing its 2026 outlook and announcing plans to restart a Phase 3 study. Sony and several Chinese tech names also slid as futures pointed lower.

Get Market Alerts

Weekly insights + SMS alerts

Tuesday's pre-market session brought a wave of selling pressure, with U.S. stock futures edging lower and Dow futures down around 0.2%.

The morning's biggest casualty was Travere Therapeutics Inc. (TVTX), which took a beating after dropping a corporate update and its 2026 outlook. The biotech company expects total U.S. net product sales of $127 million for the fourth quarter, with full-year 2025 U.S. net product sales projected at $410 million. Perhaps more significantly, Travere announced it will restart its Phase 3 HARMONY study in the first quarter of 2026.

The market wasn't thrilled with the news. Travere Therapeutics shares cratered 28.2% to $24.50 in pre-market trading.

But Travere wasn't alone in the pre-market pain. Here's who else was taking hits before the opening bell:

Lulu's Fashion Lounge Holdings Inc. (LVLU) gave back some of Monday's euphoria, sliding 10.4% to $10.89. The fashion retailer had surged 79% the previous session after Friedland Enterprises scooped up a 5% stake in the company.

Graf Global Corp (GRAF) tumbled 7% to $10.00 in pre-market action.

Ready Capital Corp (RC) declined 4.3% to $2.01 before the bell.

Chinese tech stocks pulled back after Monday's rally. Baidu Inc. (BIDU) dropped 3.9% to $146.40 after gaining 6% on Monday, while PDD Holdings Inc. (PDD) fell 3.8% to $114.22.

Amrize AG (AMRZ) dipped 3.7% to $55.51, and DeFi Technologies Inc. (DEFT) declined 3.7% to $1.04 in early trading.

Kingsoft Cloud Holdings Ltd (KC) fell 3.5% to $12.93, reversing some of Monday's impressive 22% jump.

Sony Group Corp (SONY) rounded out the decliners, falling 3.3% to $24.34 in pre-market trading.